Topic: Mebendazole

Dr. Makis details the mechanisms by which Ivermectin, Fenbendazole, and Mebendazole combat cancer, including the targeting of cancer stem cells and reversing chemo-resistance. He notes that Johns Hopkins holds a patent on Mebendazole for brain cancer, yet the information is suppressed. The segment also covers the high excess mortality in Japan and the growing resistance among Japanese doctors.

Research papers are reviewed suggesting that Fenbendazole, a common deworming medication, possesses at least 12 anti-cancer mechanisms, including the inhibition of glucose transport in cancer cells. Despite these findings, the drug remains largely ignored by mainstream oncology in favor of expensive chemotherapy. The segment notes that a similar drug, Mebendazole, is already undergoing FDA-approved clinical trials for brain and colon cancers.